secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001193125-26-084154
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint doses first patients in Phase 3 DME trials for DURAVYU; topline data 2H 2027
--------------------------------------------------------------------------------

- First patients dosed in global Phase 3 COMO and CAPRI trials of DURAVYU (vorolanib intravitreal insert) for diabetic macular edema.
- DURAVYU is a sustained-release TKI inhibiting VEGF, PDGF, and IL-6; design based on positive Phase 2 VERONA results.
- Non-inferiority trials vs aflibercept; ~240 patients each; primary endpoint BCVA change at weeks 52 and 56.
- DURAVYU 2.7mg administered via standard intravitreal injection every six months; topline data anticipated 2H 2027.
- Program aligns with FDA and EMA after End of Phase 2 meeting; aims to reduce treatment burden for DME patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000119312526084154/0001193125-26-084154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000119312526084154/eypt-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-084154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer